Doxorubicin gradients in human breast cancer
- PMID: 10430072
Doxorubicin gradients in human breast cancer
Abstract
Ten patients with locally advanced breast cancer were given doxorubicin i.v., and an incision biopsy was subsequently taken. Doxorubicin autofluorescence was examined using computerized laser scanning microscopy, and microvessels were immunostained in the same sections. Overlays of both pictures revealed doxorubicin gradients in tumor islets with high concentrations in the periphery and low concentrations in the center of the tumor islets. Gradients were most pronounced shortly after the injection, but they could still be detected 24 h later. No gradients were observed in connective tissue. This study demonstrates a serious risk of the drug not reaching all of the cancer cells in those cases in which the cancer cells are densely packed in islets. The efficacy of drug treatment will thus depend on the histology of the tumor tissue.
Comment in
-
Understanding barriers to drug delivery: high resolution in vivo imaging is key.Clin Cancer Res. 1999 Jul;5(7):1605-6. Clin Cancer Res. 1999. PMID: 10430057 No abstract available.
Similar articles
-
A mathematical model of drug transport in human breast cancer.Microvasc Res. 2000 Jan;59(1):149-61. doi: 10.1006/mvre.1999.2218. Microvasc Res. 2000. PMID: 10625582
-
Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer.Cancer Chemother Pharmacol. 2001 Oct;48(4):333-7. doi: 10.1007/s002800100297. Cancer Chemother Pharmacol. 2001. PMID: 11710635 Clinical Trial.
-
Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes.Cancer. 1999 Jul 1;86(1):72-8. Cancer. 1999. PMID: 10391566
-
Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations.Cancer Invest. 2001;19(2):155-64. doi: 10.1081/cnv-100000150. Cancer Invest. 2001. PMID: 11296620 Review.
-
Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer.Expert Rev Anticancer Ther. 2002 Apr;2(2):143-50. doi: 10.1586/14737140.2.2.143. Expert Rev Anticancer Ther. 2002. PMID: 12113236 Review.
Cited by
-
Doxorubicin Anticancer Drug Monitoring by ds-DNA-Based Electrochemical Biosensor in Clinical Samples.Micromachines (Basel). 2021 Jul 9;12(7):808. doi: 10.3390/mi12070808. Micromachines (Basel). 2021. PMID: 34357218 Free PMC article.
-
Doxorubicin concentrations in bone tumour-relevant tissues after bolus and continuous infusion: a randomized porcine microdialysis study.Cancer Chemother Pharmacol. 2024 Jun;93(6):555-564. doi: 10.1007/s00280-023-04637-1. Epub 2024 Feb 8. Cancer Chemother Pharmacol. 2024. PMID: 38332155 Free PMC article.
-
Microfluidic-assisted preparation of RGD-decorated nanoparticles: exploring integrin-facilitated uptake in cancer cell lines.Sci Rep. 2020 Sep 2;10(1):14505. doi: 10.1038/s41598-020-71396-x. Sci Rep. 2020. PMID: 32879363 Free PMC article.
-
Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities.Crit Rev Biomed Eng. 2012;40(1):21-41. doi: 10.1615/critrevbiomedeng.v40.i1.20. Crit Rev Biomed Eng. 2012. PMID: 22428797 Free PMC article. Review.
-
Simultaneous detection of intracellular target and off-target binding of small molecule cancer drugs at nanomolar concentrations.Br J Pharmacol. 2010 Jun;160(4):958-70. doi: 10.1111/j.1476-5381.2010.00732.x. Br J Pharmacol. 2010. PMID: 20590591 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical